Ruiz-Argüelles G J, Lagunes-Yannelli B, Mercado-Díaz L, Alemán-Hoey D D
Centro de Hematología y Medicina Interna de Puebla, México.
Rev Invest Clin. 1994 Nov-Dec;46(6):491-3.
In this prospective study we analyze the long-term survival using 300 mg/day zidovudine (AZT) in patients with advanced forms of human immunodeficiency virus infection. The study is in a private-practice setting, over a 5-year period, and includes 72 patients with advanced human immunodeficiency virus infection (categories C1, 2 or 3). The median survival (SV) is above 60 months (24-months SV 65% and 60-month SV 54%). According to the number of CD4 cells at diagnosis it was found that patients with above or below 200 CD4 T cells had a median SV of above 60 and 18 months (p < 0.001) and a 24-month SV 88 and 45% (p < 0.001); for patients with CD4 cells below 20 at diagnosis, the median survival was even lower (three months) and the 12-month survival less than 18%. It is concluded that the results of treating HIV-infected patients with AZT 300 mg/day are similar to those reported by others using higher doses of AZT. A low dosage is also more easily available to a larger number of HIV-infected individuals.
在这项前瞻性研究中，我们分析了使用每日300毫克齐多夫定（AZT）治疗晚期人类免疫缺陷病毒感染患者的长期生存率。该研究在私人诊所环境中进行，为期5年，纳入了72例晚期人类免疫缺陷病毒感染患者（C1、2或3类）。中位生存期（SV）超过60个月（24个月生存率为65%，60个月生存率为54%）。根据诊断时CD4细胞的数量发现，诊断时CD4 T细胞高于或低于200的患者，中位生存期分别超过60个月和18个月（p<0.001），24个月生存率分别为88%和45%（p<0.001）；诊断时CD4细胞低于20的患者，中位生存期更低（3个月），12个月生存率低于18%。得出的结论是，每日使用300毫克AZT治疗HIV感染患者的结果与其他人使用更高剂量AZT所报告的结果相似。低剂量对于更多HIV感染个体来说也更容易获得。
